The Circulating Levels of Cardiac Natriuretic Hormones in Healthy Adults: Effects of Age and Sex

Clerico, Aldo; Ry, Silvia Del; Maffei, Silvia; Prontera, Concetta; Emdin, Michele; Giannessi, Daniela

doi:10.1515/cclm.2002.060

Cited by 111 publications

(87 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with previous publications [6][7][8][9][10][11][12] , the levels of both natriuretic peptides increased with severity of the heart impairment. The highly significant relationship to age and gender for both natriuretic peptides found, accords with other studies [13][14][15][16][17][18] . Diuretics, ACE inhibitors, angiotensin receptor antagonists, betablockers and renal impairment have been shown to decrease levels of natriuretic peptides 19 .…”

Section: Discussionsupporting

confidence: 92%

Evidence for Natriuretic Peptides a and B as Non-Invasive Markers in Congenital and Valvular Heart Disease

Kotaška¹,

Průša²

2010

BIOMED PAP

View full text Add to dashboard Cite

Aim. The aim of this study was to evaluate the diagnostic utility of natriuretic peptides of type A and B as noninvasive markers in the diagnosis and treatment of congenital and valvular heart disease.Methods. Blood samples from 82 patients with various congenital and valvular heart diseases were measured for A and B natriuretic peptide levels and levels compared with those in a reference group of blood donors. Electrochemiluminiscence immunoassay and immunoluminometric essay were used for quantification of natriuretic peptides A and B. Particular reference values in serum or plasma of blood donors were adapted from literature.Results. Natriuretic peptide levels in cardiac patients were significantly higher than reference levels. The levels of both peptides in blood serum or plasma showed positive correlation with age, gender and disease severity.Conclusions. Natriuretic peptides are efficient, non-invasive cardiac markers for facilitating diagnosis, management and treatment of valvular heart disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Evidence for Natriuretic Peptides a and B as Non-Invasive Markers in Congenital and Valvular Heart Disease

Kotaška¹,

Průša²

2010

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…The advised cutoff value for this group is 155 ng l À1 , using our cutoff point of 200 ng l À1 did not make any difference in our study population. For ANP, no differences in levels between men and women are described and a correlation with age is weaker than described in BNP (Clerico et al, 2002). The serum concentration of NT-proBNP was elevated in all patients with CHD.…”

Section: Resultsmentioning

confidence: 72%

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

et al. 2004

View full text Add to dashboard Cite

Carcinoid heart disease (CHD) occurs in 20 -70% of the patients with metastatic well-differentiated neuroendocrine tumours (NET). We evaluated whether natriuretic peptides (ANP or NT-proBNP) are useful in early detection of CHD. Blood samples from 32 patients with NET were compared with cardiac ultrasound follow-up. CHD was defined as thickening of the tricuspid valve in the presence of grade III -IV/IV tricuspid valve regurgitation. CHD was found in nine out of 32 patients (28%), all with symptoms of the carcinoid syndrome compared to 65% in the 23 patients without CHD (P ¼ 0.04). Median levels of NT-proBNP and 5-HIAA were significantly higher in patients with CHD (894 ng l À1 and 815 mmol 24 h À1 ) compared to those without (89 and 206 ng l À1 , Po0.001 and P ¼ 0.007). No significant differences were detected in ANP levels (P ¼ 0.11). Dilatation of the right atrium and ventricle as well as thickening of the tricuspid valve and degree of regurgitation were statistically significant correlated with NT-proBNP levels. The accuracy of NT-proBNP in the diagnosis of CHD was higher than that of ANP. A significantly better survival was observed in case of normal NT-proBNP values. In conclusion, NT-proBNP is helpful as a simple marker in the diagnosis of CHD. Survival is better in patients with normal levels of NT-proBNP.

show abstract

“…In the studies previously performed in newborns and children, gender difference was not investigated. In the study performed by Clerico et al (13), BNP levels of healthy women (12.2±10.2 pg/ml) were compared with BNP levels of healthy men (7.7±7.1 pg/ml) and BNP levels of the women were found to be significantly higher. This result was attributed to female sex hormones.…”

Section: Discussionmentioning

confidence: 97%

Erken doğmuş bebeklerde beyin natriüretik peptit düzeyi ile patent duktus arteriyozus arasındaki ilişki

...

2012

Tpa

View full text Add to dashboard Cite

Aim: To compare brain natriuretic peptide level and some of the echocardiographic parameters of premature infants and to search its value for the diagnosis of patent ductus arteriosus. Patients with patent ductus arteriosus constituted Group 1 (n=20) and patients without patent ductus arteriosus constituted Group 2 (n=30). The diagnosis of patent ductus arteriosus was made by M-mode and Doppler echocardiography on the 7 th day postnatally. Ductus diameter, left atrium aortic root diameter ratio, left ventricular end diastolic diameter, interventricular septum thickness, left ventricular posterior wall thickness, ejection fraction and fractional shortening were evaluated. The infants with hemodynamically significant patent ductus arteriosus were treated. Brain natriuretic peptide was evaluated on the 1 st , 3 rd and 7 th days of postnatal age in all patients and also on the 3 rd day after treatment. For statistical analysis SPSS for Windows 15.0 was used. The study was conducted after obtaining informed consent from the patients and was approved with the decision of the ethics committee (number 231, date 12-6-2009). Results: Sex, gestational age and birth weight were similar in both grups. When brain natriuretic peptide level was compared with ductus diameter, left atrium aortic root diameter ratio and left ventricular end diastolic diameter values, the results were found to be statistically significant (p<0.05). When comparison was made with interventricular septum thickness, left ventricular posterior wall thickness, ejection fraction and fractional shortening values, the results were found to be statistically insignificant (p>0.05). Brain natriuretic peptide level decreased significantly after treatment. Conclusions: Brain natriuretic peptide level was found be higher in infants with patent ductus arteriosus compared to infants without patent ductus arteriosus. It was shown that ductus diameter, left atrium aortic root diameter ratio and left ventricular end diastolic diameter were related with brain natriuretic peptide levels. (Turk Arch Ped 2012; 47: 92-6) Key words: Patent ductus arteriosus, brain natriuretic peptide, premature infant, echocardiography, atrial natriuretic peptide, left atrium aortic root diameter ratio, left ventricular end diastolic diameter.

show abstract

The Circulating Levels of Cardiac Natriuretic Hormones in Healthy Adults: Effects of Age and Sex

Cited by 111 publications

References 33 publications

Evidence for Natriuretic Peptides a and B as Non-Invasive Markers in Congenital and Valvular Heart Disease

Evidence for Natriuretic Peptides a and B as Non-Invasive Markers in Congenital and Valvular Heart Disease

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

Erken doğmuş bebeklerde beyin natriüretik peptit düzeyi ile patent duktus arteriyozus arasındaki ilişki

Contact Info

Product

Resources

About